Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Key Takeaways
- Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand.
- Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
- Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Read Complete Original Article
Published originally on CNBC Business






